8-K: TG Therapeutics Exceeds Expectations with Strong BRIUMVI Sales, Raises Full-Year Revenue Guidance

TG Therapeutics reported strong third-quarter 2024 results, driven by robust sales of BRIUMVI, and raised its full-year revenue guidance for the drug.

Summary

• TG Therapeutics announced its third-quarter 2024 financial results, highlighting significant growth in BRIUMVI sales.
• U.S. BRIUMVI net revenue reached $83.3 million for the quarter, a 15% increase compared to the previous quarter and over 230% growth from the same quarter last year.
• The company has raised its full-year 2024 U.S. BRIUMVI net revenue target to $300 $305 million, up from the previous guidance of $290 $300 million.
• Total revenue for the quarter was $83.9 million, compared to $165.8 million in the same quarter of 2023, which included a large one-time licensing payment.
• Net income for the quarter was $3.9 million, a decrease from $113.9 million in the same quarter of 2023, due to the absence of the large licensing payment.
• The company's cash, cash equivalents, and investment securities totaled $341 million as of September 30, 2024.
• TG Therapeutics anticipates that its current cash position and projected BRIUMVI revenues will be sufficient to fund its business based on its current operating plan.

Sentiment

Score: 9

Explanation: The document conveys a very positive sentiment due to strong sales growth, raised revenue guidance, positive clinical data, and pipeline advancements. The company's financial position is also strong, and management's comments are optimistic.

Positives

• BRIUMVI sales are exceeding expectations, leading to increased revenue guidance.
• Clinical data shows strong efficacy and safety profile for BRIUMVI over five years.
• The company is making progress in developing faster infusion times and subcutaneous options for BRIUMVI.
• The company has secured a secondary manufacturer for BRIUMVI, mitigating supply chain risks.
• The company has a strong cash position of $341 million.
• The company is expanding its pipeline with new clinical trials for subcutaneous ublituximab and azer-cel.

Negatives

• Net income decreased significantly compared to the same quarter last year due to the absence of a large one-time licensing payment.
• Total revenue decreased compared to the same quarter last year due to the absence of a large one-time licensing payment.
• R&D and SG&A expenses have increased compared to the same period last year.

Risks

• The company's ability to maintain and continue to maintain a commercial infrastructure for BRIUMVI is a risk.
• There is a risk that trends in prescriptions are not maintained or that prescriptions are not filled.
• The company faces the risk of failure to obtain and maintain payor coverage.
• There is a risk that healthcare professional interest in BRIUMVI will not be sustained.
• The company faces the risk that momentum in sales for BRIUMVI will not build during the course of the year.
• There is a risk that the commercialization of BRIUMVI does not continue to exceed expectations.
• The company faces the risk that its current or future BRIUMVI revenue targets will not be achieved.
• The company faces the risk of failure to obtain and maintain requisite regulatory approvals.
• There is a risk that the company fails to satisfy post-approval regulatory requirements.
• The company faces the potential for variation from its projections and estimates about the potential market for BRIUMVI.
• The company faces the risk of further limitations that regulators may impose on the required labeling for BRIUMVI.
• The company faces the risk of not meeting post-approval compliance obligations.
• The company relies on third parties for manufacturing, distribution and supply, and other support functions for its clinical and commercial products.
• The company faces potential regulatory challenges to its plans to seek marketing approval for the product in jurisdictions outside of the U.S.
• The company faces the uncertainties inherent in research and development.
• There is a risk that any individual patient's clinical experience in the post-marketing setting, or the aggregate patient experience in the post-marketing setting, may differ from that demonstrated in controlled clinical trials.
• The company faces the risk that it does not achieve its 2024 development pipeline anticipated milestones in the timeframe projected or at all.
• The company faces general political, economic, and business conditions.

Future Outlook

The company anticipates continued growth in BRIUMVI sales into the end of 2024 and into 2025, and is focused on further progress both commercially and clinically. They expect their cash position and projected revenues to be sufficient to fund their business based on their current operating plan.

Management Comments

• Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated that the positive feedback and uptake of BRIUMVI in the marketplace continues to outpace their expectations.
• Mr. Weiss also mentioned that the company is focused on individuals living with relapsing forms of multiple sclerosis and is making strides with clinical programs to improve their treatment experience.
• Mr. Weiss expressed excitement for further progress in 2025 both commercially and clinically.

Industry Context

This announcement reflects a positive trend in the multiple sclerosis treatment market, where new therapies like BRIUMVI are gaining traction. The focus on improving treatment experience, such as shorter infusion times and subcutaneous options, aligns with the industry's move towards patient-centric care. The company's success in commercializing BRIUMVI and expanding its pipeline positions it well against competitors in the MS space.

Comparison to Industry Standards

• The 230% year-over-year growth in BRIUMVI sales is significantly higher than the average growth rate for established MS therapies, indicating strong market adoption.
• The five-year data showing 92% of patients free from disability progression is competitive with other long-term MS treatments, such as Ocrevus and Kesimpta.
• The development of a 30-minute infusion option for BRIUMVI is a significant advantage compared to other anti-CD20 therapies that require longer infusion times, such as Rituxan.
• The initiation of a subcutaneous ublituximab trial positions TG Therapeutics to compete with other subcutaneous MS treatments like Kesimpta and Tysabri.
• The company's focus on developing novel treatments like allogeneic CD19 CAR-T sets it apart from competitors who are primarily focused on monoclonal antibodies.

Stakeholder Impact

• Shareholders will likely react positively to the strong sales growth and increased revenue guidance.
• Employees may feel more secure due to the company's positive financial performance and growth prospects.
• Patients will benefit from the availability of BRIUMVI and the development of new treatment options.
• Suppliers and creditors may view the company as a more reliable partner due to its strong financial position.

Next Steps

• The company will continue to commercialize BRIUMVI in the U.S. and Europe.
• They will study BRIUMVI in an additional autoimmune disease outside of MS.
• They will commence a clinical trial evaluating azer-cel in autoimmune diseases, starting with progressive MS.
• They will continue to develop subcutaneous BRIUMVI.
• The company will host a conference call to discuss the financial results.

Key Dates

Keywords

BRIUMVI, ublituximab, multiple sclerosis, RMS, TGTX, biopharmaceutical, CD20, autoimmune, revenue, clinical trial